Abstract CT179: ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma

2019 ◽  
Author(s):  
Petros Grivas ◽  
Min Yuen Teo ◽  
Nicholas Vogelzang ◽  
Ajjai Alva ◽  
Yousef Zakharia ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Locally Advanced ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Metastatic Urothelial Carcinoma

ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS4592-TPS4592 ◽  
Author(s):  
Petros Grivas ◽  
Dale L. Nepert ◽  
Kenton Wride ◽  
Daleen Thomas ◽  
Andrea Loehr ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Locally Advanced ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Metastatic Urothelial Carcinoma

ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma

2019 ◽  
Vol 18 (1) ◽  
pp. e1838-e1839
Author(s):  
A. Rodriguez-Vida ◽  
S. Feyerabend ◽  
Y. Loriot ◽  
A. Necchi ◽  
S. Gupta ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Locally Advanced ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Metastatic Urothelial Carcinoma

scholarly journals A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

2005 ◽  
Vol 57 (4) ◽  
pp. 533-539 ◽  
Author(s):  
Monika Jermann ◽  
Rolf A Stahel ◽  
Marc Salzberg ◽  
Thomas Cerny ◽  
Markus Joerger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Locally Advanced ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document